Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Tracheal Diseases 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1Laryngeal Diseases 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

pembrolizumab 4Injections 3Nivolumab 2Docetaxel 2taxane 1pazopanib 1palbociclib 1lenvatinib 1demplatin pegraglumer 1cobimetinib 1birinapant 1Topotecan 1Tablets 1ODM-207 1Infusions, Intravenous 1HLA-A*24:02 antigen 1Gemcitabine 1E-3810 1CB-839 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Tumors × Tablets × Clear all
NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Calithera Biosciences, Inc

Phase 1/2 Completed
53 enrolled
Other solid neoplasmThoracic

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡